NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 137 filers reported holding NEKTAR THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 5.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,116 | -80.2% | 28,738 | -80.9% | 0.00% | -77.8% |
| Q2 2023 | $86,369 | -18.2% | 150,154 | 0.0% | 0.01% | -10.0% |
| Q1 2023 | $105,543 | -81.0% | 150,154 | -39.0% | 0.01% | -84.6% |
| Q4 2022 | $556,236 | -44.3% | 246,122 | -21.1% | 0.06% | -16.7% |
| Q3 2022 | $999,000 | -9.5% | 312,107 | +7.4% | 0.08% | -14.3% |
| Q2 2022 | $1,104,000 | +102.2% | 290,489 | +186.9% | 0.09% | +97.8% |
| Q1 2022 | $546,000 | +23.0% | 101,237 | +208.3% | 0.05% | +17.9% |
| Q4 2021 | $444,000 | -34.5% | 32,835 | -13.0% | 0.04% | -51.9% |
| Q3 2021 | $678,000 | +289.7% | 37,759 | +273.3% | 0.08% | +200.0% |
| Q2 2021 | $174,000 | -56.7% | 10,114 | -57.2% | 0.03% | -78.6% |
| Q4 2020 | $402,000 | – | 23,644 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |